Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Prostate Cancer: Update Bulletin [April 2017]

Product Code:
596200725
April Date:
April 2017
Format:
PDF
Price:
£1,140

Gain new key opinion leader (KOL) insights on the latest events happening in prostate cancer. Topics covered include expert opinions on the two oral PARP inhibitors (AstraZeneca’s Lynparza [olaparib] and Clovis Oncology’s rucaparib) that are in Phase III development for men with metastatic castration-resistant prostate cancer (mCRPC). KOLs also provide their first insights on the IMbassador250 Phase III study that was initiated in January 2017 investigating Roche’s anti-programmed death-ligand 1 (PD-L1) checkpoint inhibitor Tecentriq (atezolizumab) in combination with Xtandi (enzalutamide) in patients with mCRPC. With Bavarian Nordic’s PROSPECT study due to complete in 2017, KOLs also discuss their expectations for the highly-anticipated study investigating the vaccine PROSTVAC (rilimogene galvacirepvec-rilimogene glafolivec) (PSA-TRICOM) in prostate cancer.

Business Questions:

  • How do KOLs view the biomarker-driven data published for AstraZeneca’s olaparib in prostate cancer?
  • What are KOL expectations for olaparib and rucaparib in patients with mCRPC and how do the drugs compare?
  • Which treatment settings do KOLs expect PARP inhibitors to gain traction?
  • How do the experts view the PD-L1 inhibitor drug class in prostate cancer?
  • How does atezolizumab compare with other PD-1/PD-L1 immune checkpoint inhibitors such as Merck & Co.’s Keytruda (pembrolizumab)?
  • What are KOL expectations for the Phase III IMbassador250 study with Roche’s atezolizumab?
  • Where will immunotherapy combinations be best utilised in patients with prostate cancer?
  • What are KOL expectations for Bavarian Nordic’s PROSPECT study with the PROSTVAC vaccine?
  • How does PROSTVAC compare to Provenge and what are the key advantages of vaccine treatment?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved